Wellysis
- Company typePrivate
- Founded2019
- HeadquartersSeoul, South Korea
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
Wellysis firmographics
Firmographics- Name
- Wellysis
- Legal name
- 주식회사 웰리시스 (Wellysis Corp.)
- Website
- https://wellysis.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Wellysis industry classification
Industry- Product category
- Wearable ECG Monitoring Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Cardiac Monitoring (ECG/Holter/Event/Patch, Loop Recorders) (HLAHACAB)
- akta.pro secondary industries
- Connected Medical Devices & Wearables (Sensors, Patches, Implantables) (HLACAPAB), Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration) (HLACAPAI), Wearables & Consumer IoT Integration Platforms (BYOD) (HLACAFAF)
Keywords
Where Wellysis is headquartered
LocationHeadquarters
- HQ city
- Seoul
- HQ country
- South Korea
- HQ region
- Asia
Offices3 records
Markets served
Wellysis business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations
Revenue model
- S-Patch Hardware Sales: Sale of wearable ECG patch devices (S-Patch Ex, S-Patch ExL) and accessories (electrodes, batteries). Reusable device with consumable electrodes and batteries.
- Software/SaaS Subscriptions: S-Patch App subscriptions, S-Patch Web platform access, and analysis services for healthcare providers. Cloud-based data processing and AI analysis services.
- Analysis Services: Professional ECG analysis services for clinics and screening centers. Includes physician report generation and clinical consultation support.
- AI Algorithm Licensing: Integration of Wellysis AI algorithms (DeepRhythmAI) with partner platforms. Revenue from algorithm licensing and integration partnerships.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | B2B Enterprise Pricing - Medical Institutions |
Go-to-market motion2 records
Distribution channels5 records
Marketing channels5 records
Wellysis product offering
Product offeringCore offering
Wellysis develops and sells the S-Patch, a lightweight (8.5–11g), reusable, waterproof wearable patch-type ECG monitor powered by Samsung's Smart Health Processor, capable of continuous ECG recording for up to 14 days. The device feeds a companion mobile app (S-Patch App), a cloud-based physician reading platform (S-Patch Web), and an AI-powered ECG analysis service (S-Patch AI / ECG Lakehouse) trained on more than 6 billion labeled heartbeats from 790+ healthcare providers.
Product overview
Wellysis offers a unified S-Patch ECG monitoring solution consisting of wearable patch devices (S-Patch Wear - including Ex, ExL, and Cardio models), companion mobile apps (S-Patch App for patient and S-Patch Medi for healthcare providers), a cloud-based web analysis platform (S-Patch Web), and AI-powered analytics (S-Patch AI/ECG Lakehouse). The product suite enables end-to-end ECG testing: patients wear the lightweight patch for 1-14 days, data syncs via Bluetooth to mobile devices and uploads to cloud, AI algorithms perform initial analysis, and physicians review/edit reports via web portal. Upcoming BioArmour extends the platform to multi-biosignal monitoring for high-risk occupations.
Differentiator
Problem solved
Functional benefit
Brands
- S-Patch: Flagship wearable ECG monitoring device line including S-Patch Ex (up to 3 days) and S-Patch ExL (up to 11-14 days) models, powered by Samsung Smart Health Processor.
- S-Patch Web
- S-Patch AI
- BioArmour
Products and services
- S-Patch Wear (Ex and ExL models) Wearable patch-type ECG monitoring device powered by Samsung Smart Health Processor. Two models: S-Patch Ex (up to 100 hours / 1–3 days) and S-Patch ExL (up to 264 hours / 3–11 days, FDA cleared for up to 14 days). Weighs 8.5–11g, IP55 waterproof, reusable with replaceable electrodes and coin-cell batteries, Bluetooth BLE 5.1 connectivity. Sold as a medical device prescribed by hospitals to clinics, hospitals, screening centers, CROs, and corporate wellness programs.
- S-Patch App (Ex) Patient-facing mobile application (iOS and Android) paired with S-Patch Wear. Provides real-time ECG waveform display, live HR and HRV monitoring, symptom and activity diary, and automatic encrypted upload of ECG data to the cloud server upon test completion. Targets patients prescribed the S-Patch Ex wearable.
- S-Patch App (Medi) Healthcare professional mobile application for managing S-Patch tests without requiring the patient's smartphone. Supports multiple simultaneous patient tests, device management, live ECG monitoring, battery level tracking, and scheduled data uploads. Used by clinicians and clinical staff in hospitals, clinics, and screening centers.
- S-Patch Web Cloud-based ECG reading and analysis web platform for physicians and clinical staff. Features test management, ECG data review with AI pre-analysis, and report generation (Physician Report, Screening Report, Full Disclosure Report) delivered as PDF documents. Sold as a subscription/SaaS service to clinics, hospitals, and screening centers, with optional professional ECG analysis services.
- S-Patch AI (ECG Lakehouse) AI-powered ECG analysis service backed by the ECG Lakehouse deep neural network platform trained on 6B+ labeled heartbeats from 1.5M+ hours of continuous ECG across 790+ healthcare providers. Capabilities include arrhythmia diagnosis, ECG clinical reports, HRV-based stress scoring, posture analysis, activity tracking, fall detection, and atrial fibrillation prediction. Delivered as an add-on analysis service for clinical customers and licensed to partner platforms (e.g., Medicalgorithmics DeepRhythmAI).
- BioArmour Next-generation wearable solution for frontline responders (firefighters, police, military, coast guards) and high-performance athletes. AI-powered multi-biosignal analysis monitoring ECG, core body temperature, body composition, and motion for early detection of abnormal signs. Multiple form factors with high durability for high-risk frontline and athletic environments. Unveiled at CES 2026 and targeted at public safety agencies and defense organizations.
Quantifiable outcome
- Detection rate increases to over 80% in 7 days vs 30% in 24 hours for traditional Holter
- +2 more outcomes
Companies that use Wellysis
Customer profileNamed customers6 records
Segments5 records
Ideal customer profiles4 records
Wellysis technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- Yes
- API docs
- API detail
Core technology
AI maturity
App detail
Integration3 records
AI capability6 records
Feature5 records
Wellysis partnerships and signals
Strategic signalPartnerships
Nine partnerships are on record, tiered core and major.
- Medicalgorithmics S.A.coreStrategic partnership with Poland-based AI-driven cardiac diagnostics company. Wellysis integrates FDA-cleared S-Patch with Medicalgorithmics' DeepRhythm Platform (DRP) and DeepRhythmAI (DRAI) algorithms for more precise, real-time patient data analysis. Expected to enhance product capabilities and support global customer expansion.
- HeartcoR SolutionscoreExclusive partnership for clinical trials. HeartcoR Solutions, a leading ECG core lab for pharmaceutical and medical device cardiac safety studies, has exclusive rights to offer S-Patch device in global clinical trials. Supports decentralized clinical trials with easy-to-use wearable ECG technology.
- Artella SolutionscorePartnership for US remote cardiac monitoring service launch. Artella provides comprehensive remote cardiac monitoring across 10 US states. Combined offering includes Samsung smartphones/smartwatches integration with S-Patch ExL. Starting in Texas with expansion plans.
- Samsung ElectronicscoreBusiness collaboration with Samsung Electronics' System LSI division for next-generation S-Patch development. Joint development agreement for wearable biosignal measurement devices using Samsung's Smart Health Processor. Includes monitoring services for high-risk occupations and corporate wellness programs.
- Kangbuk Samsung HospitalmajorCorporate cardiovascular disease prevention program with Kangbuk Samsung Hospital and Samsung Electronics. Provides full-covered health management services within workplace using S-Patch ECG tests for Samsung DS employees.
- DozeecorePartnership with India's prominent bed monitoring solutions provider. S-Patch devices to be integrated into 50,000 of Dozee's hospital beds starting January 2024, following successful product launch event in New Delhi.
- Samjin Pharmaceutical Co., Ltd.coreExclusive distributor and investment contract. Samjin Pharmaceutical distributes S-Patch Cardio in Korean domestic market. Partnership enables wide distribution from primary care clinics to tertiary hospitals.
- Stanford University School of MedicinemajorResearch collaboration for COVID-19 wearable project monitoring recovered patients. Stanford uses S-Patch Cardio in project involving 1,000 recovered COVID-19 patients to study cardiovascular health impacts.
- Apollo Hospitals (India)majorJoint development MOU signed for cardiac monitoring solutions. Apollo operates 40+ heart disease centers across India. Partnership for market expansion in India.
Scale indicators8 records
Recent moves9 records
Expansion highlights8 records
Wellysis competitors and assessment
Company assessmentDirect peers
- Eko Health: Eko develops AI-powered digital stethoscopes with ECG and cardiac auscultation analysis, including SENSORA cardiac AI platform. Comparable to Wellysis in AI-driven cardiac diagnostics and expanding into multi-biosignal wearables for clinicians.
- VivaLNK: VivaLNK makes wearable ECG patches and connected health sensors for remote patient monitoring. Direct comparable to S-Patch in form factor and continuous monitoring use cases, also serving clinical trial and RPM customers. (Also notable as the prior employer of Wellysis's CCO.)
- Medicalgorithmics: Medicalgorithmics is a Poland-based cardiac diagnostics AI company offering DeepRhythm Platform (DRP) and DeepRhythmAI algorithms. Already a strategic integration partner of Wellysis, with overlapping AI ECG analysis capabilities and customer base in pharma clinical trials.
- AliveCor: AliveCor's KardiaMobile is a single/6-lead ECG device for consumer and clinical AF detection, with AI-based interpretation. Competes with Wellysis in clinical-grade ECG AI and offers an alternative delivery model (handheld vs patch).
- iRhythm Technologies: iRhythm is the leading US patch-based cardiac monitor (Zio) with strong CMS reimbursement and a deep clinical evidence base. Direct competitor to Wellysis's S-Patch in the ambulatory ECG monitoring segment, with overlap in arrhythmia detection AI and enterprise hospital sales motion.
Broad incumbents
- Apple (Apple Watch ECG): Apple Watch offers single-lead ECG with FDA-cleared AF detection for consumer use. A broad incumbent shaping consumer expectations around wearable ECG and indirectly competing for cardiac monitoring mindshare, though limited to consumer/wrist-based form factor.
- Boston Scientific (Preventice Solutions): Boston Scientific acquired Preventice Solutions, which offers BodyGuardian remote cardiac monitoring. A larger incumbent with established US sales infrastructure, deep reimbursement, and broader cardiology device portfolio competing for hospital accounts.
- Philips (BioTelemetry): Philips acquired BioTelemetry, one of the largest US ambulatory cardiac monitoring providers (MCOT, Holter). A broad incumbent offering overlapping remote cardiac monitoring and AI analysis services to Wellysis's target hospital segment.
Emerging players
- Dozee: Dozee is India's leading bed-based contactless patient monitoring company, integrating Wellysis S-Patch into 50,000 hospital beds. Comparable in remote patient monitoring for hospital inpatients, focused primarily on South Asia with growing international expansion.
Regional players
- HeartcoR Solutions: HeartcoR is a US-based ECG core lab focused on cardiac safety studies for pharma and medical device clinical trials. Exclusive channel partner of Wellysis for clinical trials; comparable in cardiac clinical services but serving a different primary customer segment (CROs vs hospitals).
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
Wellysis social profiles
Digital presenceWellysis compliance and trust
Trust signalCompliance9 records
Wellysis financial estimates
Financial estimateRevenue estimate
Valuation estimate
Wellysis leadership team
Management profileNumber of profiles
Profiles6 records
Wellysis subsidiaries and ownership
Company hierarchySubsidiaries1 record
Wellysis funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Wellysis M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Wellysis
What does Wellysis do?
Wellysis develops and sells the S-Patch, a lightweight (8.5–11g), reusable, waterproof wearable patch-type ECG monitor powered by Samsung's Smart Health Processor, capable of continuous ECG recording for up to 14 days. The device feeds a companion mobile app (S-Patch App), a cloud-based physician reading platform (S-Patch Web), and an AI-powered ECG analysis service (S-Patch AI / ECG Lakehouse) trained on more than 6 billion labeled heartbeats from 790+ healthcare providers.
Is Wellysis a public or private company?
Wellysis is a private company. It is classified as venture growth investor backed and is currently operating.
When was Wellysis founded?
Wellysis was founded in 2019. It employs 11 to 50 people.
Where is Wellysis based?
Wellysis is headquartered in Seoul, South Korea, in the Asia region.
How does Wellysis make money?
Four revenue lines are on record. S-Patch Hardware Sales are the primary driver. The others are software/SaaS Subscriptions, analysis Services and AI Algorithm Licensing.
Who are Wellysis's main competitors?
Direct peers on record are Eko Health, VivaLNK, Medicalgorithmics, AliveCor and iRhythm Technologies. Broad incumbents are Apple (Apple Watch ECG), Boston Scientific (Preventice Solutions) and Philips (BioTelemetry). Dozee is listed as an emerging player. HeartcoR Solutions is listed as a regional player.
Does Wellysis have an API?
Yes. Wellysis offers SDK and API options for product integration. The inquiry form includes categories for 'SDK', 'API', and 'Inquiries' under product interest options, indicating availability for developers. Specific details on API type (REST, GraphQL, etc.), authentication methods, rate limits, versioning, or sandbox availability are not specified in the provided source material.
What industry is Wellysis in?
Wellysis's product category is Wearable ECG Monitoring Devices. Its primary akta.pro industry code is HLAHACAB, Cardiac Monitoring (ECG/Holter/Event/Patch, Loop Recorders), with a secondary code of HLACAPAB, Connected Medical Devices & Wearables (Sensors, Patches, Implantables). Its NAICS code is 334510 and its SIC code is 3845.